Business Context and Reporting Period
Company: MEDICINOVA, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: MediciNova is a development-stage biopharmaceutical company focused on acquiring and developing novel small molecule therapeutics. The company has no approved products for commercial sale and has incurred significant operating losses since inception. Its primary focus is on two prioritized product candidates: MN-221 (for asthma and COPD) and MN-166/AV411 (for CNS disorders, following the December 2009 acquisition of Avigen, Inc.).
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 | YTD Inception (Mar 31, 2010) |
|---|---|---|---|
| Revenues | $0 | $0 | $1,558,227 |
| Net Loss | $(5,161,250) | $(4,993,391) | $(221,149,227) |
| Net Loss Per Share (Basic/Diluted) | $(0.42) | $(0.41) | N/A |
| Operating Expenses | $5,236,408 | $5,265,095 | $240,067,694 |
| Cash and Cash Equivalents | $15,597,457 | $19,297,284 (Beg. Q1 2009) | N/A |
| Total Assets | $85,701,171 | N/A | N/A |
| Total Liabilities | $48,593,395 | N/A | N/A |
| Stockholders' Equity | $37,107,776 | N/A | N/A |
Liquidity Position: As of March 31, 2010, the company held approximately $24.9 million in cash, cash equivalents, current investment securities, and ARS put, net of the ARS loan. Management believes this is sufficient to fund operations through at least March 31, 2011.
Material Changes vs. Prior Period
- Net Loss: Increased slightly to $5.16 million in Q1 2010 from $4.99 million in Q1 2009.
- Operating Expenses: Remained relatively flat at $5.24 million compared to $5.27 million in the prior year.
- Research & Development (R&D): Decreased to $2.95 million (from $3.10 million), driven by reduced spending on non-prioritized programs, offset by increased spending on MN-221 clinical trials.
- General & Administrative (G&A): Increased to $2.29 million (from $2.16 million), primarily due to higher third-party consultant fees.
- Investment Securities: Recorded a net impairment charge of $7,479 on investment securities, compared to a gain of $26,671 in the prior year. This reflects a $241,000 decrease in the fair value of current ARS, partially offset by a $229,000 gain on the ARS Put and a $5,000 gain on long-term investments.
- Cash Flow: Net cash used in operating activities increased to $5.59 million (from $4.61 million), primarily due to the payment of accrued compensation expenses. Net cash provided by investing activities was $3.39 million, driven by the redemption of investment securities.
Guidance, Outlook, and Risks
- Outlook: The company expects to incur substantial net losses for the foreseeable future as it continues development of MN-221 and MN-166/AV411. No revenues are expected from product sales in the near term.
- Subsequent Event (Financing): On May 10, 2010, the company entered into a $15.0 million term loan with Oxford Finance Corporation. The loan is secured by substantially all assets (excluding IP) and includes a warrant for 198,020 shares. Proceeds are intended for working capital and MN-221 development.
- Legal Proceedings: A preliminary settlement was approved on April 6, 2010, regarding a lawsuit filed by The Pennsylvania Avenue Funds alleging breach of fiduciary duties related to the Avigen merger. The company agreed not to oppose a fee motion up to $140,000 and an incentive award up to $2,500. A final hearing is scheduled for June 24, 2010.
- Key Risks:
- Liquidity of Investments: Significant portion of assets is held in Auction Rate Securities (ARS), which have failed to auction due to credit market conditions. While the company has an ARS Put option with UBS to sell at par starting June 30, 2010, liquidity remains a concern.
- Capital Requirements: Failure to secure additional funding or strategic collaborations could force the company to delay or terminate development programs.
- Regulatory Approval: Success depends entirely on the successful completion of clinical trials and FDA approval for MN-221 and MN-166/AV411.
Investor Verification Checklist
- ARS Liquidity: Verify the status of the ARS Put option with UBS and the company's ability to liquidate these assets at par value starting June 30, 2010.
- Debt Covenants: Review the specific covenants in the new $15 million Oxford Finance loan, particularly the requirement to secure a collaboration or positive Phase IIB data by March 31, 2011.
- Cash Runway: Confirm the accuracy of the management's projection that current funds will sustain operations through March 31, 2011, given the burn rate of ~$5.2 million per quarter.
- Legal Settlement: Monitor the final settlement hearing on June 24, 2010, regarding the Avigen merger litigation to ensure no additional liabilities arise.
- Convertible Notes: Track the conversion activity of the $27.6 million in convertible notes issued during the Avigen merger, which mature in June 2011.